Baby Canopy Growth So, what’s so great about Hexo?
The stock has soared 413% over the past year, and while you think it’s a stock that’s gotten “too high” and is thus comparable with Tilray or Canopy, I’d argue that there remains substantially more upside for the $1.5 billion Quebec-based cannabis firm.
Not only is Hexo a preferred choice in the books of many Qubecois (they love their local companies and brands!), but like Canopy, the company already has an alcohol firm relationship in the bag.
The only difference is that Hexo isn’t as well known and isn’t available to buy for U.S. (or international) investors unless they’re willing to make the jump to the S&P/TSX Composite Index. Moreover, Hexo recently underwent a name change from Hydropothecary, which should be easier for prospective investors to talk about (and remember).